Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene–Related Peptide Monoclonal Antibodies (P5-12.007)

Evaluate the benefit-risk assessment of atogepant and calcitonin gene– related peptide (CGRP) monoclonal antibodies (mAbs) vs placebo based on number needed to treat (NNT) and number needed to harm (NNH) in a blended episodic and chronic migraine population (EM+CM).